Therapeutic Agents
US-2018237784-A1 · Aug 23, 2018 · US
Therapeutic agents
US11248230B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11248230-B2 |
| Application number | US-201916432645-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 5, 2019 |
| Priority date | Jul 28, 2015 |
| Publication date | Feb 15, 2022 |
| Grant date | Feb 15, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention related to identification of therapeutic agents of the treatment, diagnosis, and prevention of pulmonary hypertension.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating hypoxic-induced pulmonary hypertension in a subject, the method comprising inhibiting ZIP12 protein levels by genetic disruption of the Slc39a12 gene using a Zinc finger nuclease technolog, or inhibiting Slc39a12 gene expression using an interfering nucleic acid, wherein the interfering nucleic acid is an antisense oligonucleotide, an siRNA, or a dsRNA, in a subject in need of such treatment. 2. A method according to claim 1 , wherein the method comprisesinhibiting Slc39a12 gene expression using the interfering nucleicacid, wherein the interfering nucleicacid is the antisense oligonucleotide, the siRNA, or the dsRNA. 3. A method according to claim 1 , wherein the antisense oligonucleotide, siRNA, or dsRNA specifically bindstoa portion of the mRNA product of Slc39a12. 4. A method according to claim 1 , whereinthe method comprises disrupting the Slc39a12 gene by usingthe Zincfingernuclease technology. 5. A method according to claim 1 , whereinthe Slc39a12 gene is disrupted or the Slc39a12 gene expression isinhibited, bytargeting exon 8 ofthe Slc39a12 gene.
Assignees
Inventors
Classifications
- G01N33/5008Primary
for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics · CPC title
related to diseases not provided for elsewhere · CPC title
Pulmonary diseases · CPC title
for diseases caused by alterations of genetic material · CPC title
Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11248230B2 cover?
- The present invention related to identification of therapeutic agents of the treatment, diagnosis, and prevention of pulmonary hypertension.
- Who is the assignee on this patent?
- Ip2Ipo Innovations Ltd
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5008. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).